How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,774 results for

Thromboembolic Disease in Pregnancy

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

3761. Evaluation of Weekly Subcutaneous Biotinylated Idraparinux Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation

thromboembolic events Additional relevant MeSH terms: Layout table for MeSH terms Atrial Fibrillation Thromboembolism Arrhythmias, Cardiac Heart Diseases Cardiovascular Diseases Pathologic Processes Embolism and Thrombosis Vascular Diseases Warfarin Idrabiotaparinux Idraparinux Biotin Anticoagulants Vitamin B Complex Vitamins Micronutrients Nutrients Growth Substances Physiological Effects of Drugs Factor Xa Inhibitors Antithrombins Serine Proteinase Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular (...) Evaluation of Weekly Subcutaneous Biotinylated Idraparinux Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results

2007 Clinical Trials

3762. A Postmarketing Study of the Risk of Venous Thromboembolism (Blood Clots), Myocardial Infarction (Heart Attacks), and Stroke Among Women Using ORTHO EVRA (Norelgestromin and Ethinyl Estradiol Contraceptive Patch) Compared With Women Who Take Oral Contrace

the patch are absorbed transdermally (through the skin) to help prevent pregnancy. This is an observational case-control study that will use data provided by a United States health care claims database and the National Death Index (NDI) to assess the risk of venous thromboembolism abbreviated as VTE (includes deep vein thrombosis abbreviated as DVT [a blood clot that forms in one or more of the deep veins of the body, usually the legs] and pulmonary embolism abbreviated as PE [a blood clot in the lungs (...) & Development, L.L.C.: Contraception Hormonal contraception Oral contraception Ethinyl estradiol Progestin Transdermal Thrombosis Venous thromboembolism Additional relevant MeSH terms: Layout table for MeSH terms Infarction Myocardial Infarction Thromboembolism Venous Thromboembolism Ischemia Pathologic Processes Necrosis Myocardial Ischemia Heart Diseases Cardiovascular Diseases Vascular Diseases Embolism and Thrombosis Estradiol Polyestradiol phosphate Ethinyl Estradiol Estradiol 3-benzoate Estradiol 17

2006 Clinical Trials

3763. Risk Factors for Venous Thromboembolism

is the presence of blood clots, usually in the legs that lead to either local problems or breathing problems if the clot moves to the lungs. This study is designed to assess both clinical conditions as well as common genetic factors that lead to more risk of deep venous thrombosis. Clinical conditions of venous thrombosis include: stroke, malignancy, and situations such as surgery, pregnancy, trauma, or travel. Condition or disease Deep Venous Thrombosis Pulmonary Embolism Study Design Go to Layout table (...) for MeSH terms Thrombosis Embolism Venous Thromboembolism Pulmonary Embolism Venous Thrombosis Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases Thromboembolism Lung Diseases Respiratory Tract Diseases

2001 Clinical Trials

3764. Safety Study of Fondaparinux Sodium to Prevent Venous Thromboembolic Events (APOLLO)

Description Go to Brief Summary: This is a multicentre, randomized, double-blind, placebo controlled study. During this study all the patients will receive background venous thromboembolism (VTE) mechanical prophylaxis with intermittent pneumatic compression (IPC). Condition or disease Intervention/treatment Phase Thromboembolism Drug: fondaparinux sodium Other: placebo Phase 3 Detailed Description: This is a multicenter, randomized, double-blind, placebo-controlled study evaluating the safety (...) Participant Data (IPD) Sharing Statement: Plan to Share IPD: Yes Plan Description: Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site. Keywords provided by GlaxoSmithKline: fondaparinux sodium DVT Prevention abdominal surgery VTE prevention venous thromboembolism pulmonary embolism Additional relevant MeSH terms: Layout table for MeSH terms Thromboembolism Embolism and Thrombosis Vascular Diseases

2002 Clinical Trials

3765. Successful thrombolysis of right atrial and ventricle thrombi in a patient with peripartum cardiomyopathy and extensive thromboembolism (PubMed)

Heart 9602087 1355-6037 EC 3.4.21.68 Tissue Plasminogen Activator AIM IM Adult Cardiomyopathies drug therapy Echocardiography, Transesophageal Female Heart Diseases diagnostic imaging drug therapy Humans Pregnancy Puerperal Disorders diagnostic imaging drug therapy Pulmonary Embolism drug therapy Thromboembolism drug therapy Thrombolytic Therapy Thrombosis diagnostic imaging drug therapy Tissue Plasminogen Activator therapeutic use 1998 1 1 1998 1 1 0 1 1998 1 1 0 0 ppublish 9415016 PMC1892304 (...) Successful thrombolysis of right atrial and ventricle thrombi in a patient with peripartum cardiomyopathy and extensive thromboembolism 9415016 1998 01 15 2016 11 24 1355-6037 78 5 1997 Nov Heart (British Cardiac Society) Heart Successful thrombolysis of right atrial and ventricle thrombi in a patient with peripartum cardiomyopathy and extensive thromboembolism. 515-6 Janssens U U Medical Clinic I, University of Aachen, Germany. Klues H G HG Hanrath P P eng Case Reports Journal Article England

Full Text available with Trip Pro

1997 Heart

3766. Genetics University of Toronto Thrombophilia Study in Women (GUTTSI): genetic and other risk factors for venous thromboembolism in women (PubMed)

Toronto hospital. The cases were 129 women aged 16-79 years with objectively confirmed VTE. Age-matched control individuals were women who were free of venous thrombosis. Neither cases nor control individuals had known cardiovascular disease. Participants were interviewed regarding personal risk factors for VTE, including smoking, history of malignancy, pregnancy, and oestrogen or oral contraceptive use. Blood specimens were analyzed for common single nucleotide polymorphisms of prothrombin, factor V (...) Genetics University of Toronto Thrombophilia Study in Women (GUTTSI): genetic and other risk factors for venous thromboembolism in women BACKGROUND: Women may be at increased risk for venous thromboembolism (VTE) as compared with men. We studied the effects of genetic and biochemical markers of thrombophilia in women, in conjunction with other established risk factors for VTE. METHOD: The present retrospective case-control study was conducted in a thrombosis treatment programme at a large

Full Text available with Trip Pro

2001 Current Controlled Trials in Cardiovascular Medicine

3767. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. (PubMed)

Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Intravenous heparin followed by oral anticoagulant therapy (e. g. with coumarin) is still the most widely used treatment for deep venous thromboembolism. Self-administered subcutaneous injections of heparin have been thought of as a promising alternative to coumarin, but the high doses required for ongoing prophylaxis have (...) raised concerns about the possible development of bone disease. Certainly, long-term heparin therapy has been reported to cause osteoporosis in both laboratory animals and humans. This study aimed to compare the efficacy and safety of unfractionated (UF) heparin with that of a low molecular weight heparin (Fragmin, Kabi Pharmacia) in the prevention of recurrent deep venous thrombosis (DVT) and pulmonary embolism (PE) in a consecutive series of patients with contraindications to coumarin therapy

1994 Thrombosis and haemostasis Controlled trial quality: uncertain

3768. Risk of venous thromboembolic disease in women A qualitative systematic review. (PubMed)

Risk of venous thromboembolic disease in women A qualitative systematic review. To review the scientific evidence on the risk and prevention of venous thromboembolic disease (VTD) associated with specific clinical factors in women.Qualitative systematic review.MEDLINE, Cochrane library, clinical practice guidelines, and referenced articles from these sources.Gender is not an independent risk factor of VTD. Absolute risks associated with each circumstance (per 1000 women-year) were: pregnancy (...) , 1.23; puerperium, 3.2; pregnancy in thrombophilic, 40; pregnancy and background of previous VTD, 110; use of third generation contraceptives, 0.3; postcoital pill, no risk; hormone replacement therapy, 0.2-5.9; tamoxifen, 3.6-12; and raloxifene, 9.5. The quality of the evidence on risk was classified as good or excellent. Evidence on prevention was scarce. Screening for thrombophilia prior to the prescription of contraceptives is not cost-effective as a strategy for prophylaxis. Use of low

2005 European journal of obstetrics, gynecology, and reproductive biology

3769. Venous thromboembolism during pregnancy. Clinical suspicion warrants evaluation. (PubMed)

diagnostic testing. There was no difference in the clinical signs or symptoms between groups with a pulmonary embolism (PE) compared to those without a PE. For those patients with negative diagnostic testing (n = 52), an alternative diagnosis was confirmed in 55.8%. Of the patients with positive diagnostic testing, 30% had a concurrent condition contributing to their pulmonary symptoms.Lack of definitive signs and symptoms of thromboembolic disease during pregnancy warrants complete evaluation (...) Venous thromboembolism during pregnancy. Clinical suspicion warrants evaluation. To determine the incidence, signs, symptoms and clinical outcomes of venous thromboembolism (VTE) during pregnancy.A retrospective review was conducted from 1997 to 2001 including women with a diagnosis or suspicion of VTE during pregnancy. Demographics and clinical characteristics of patients with a suspicion for VTE were reviewed.Of 70 patients assessed for evidence of a VTE, 25.7% (n = 18) had confirmatory

2003 Journal of Reproductive Medicine

3770. Cardiovascular and thromboembolic events following hypertensive pregnancy. (PubMed)

Cardiovascular and thromboembolic events following hypertensive pregnancy. Hypertension is a common complication of pregnancy. Previous evidence has linked pregnancy-related hypertension to maternal cardiovascular disease. We conducted a population-based cohort study to estimate the risks for cardiovascular and thromboembolic events in women with pregnancy-related hypertension.We analyzed data from all singleton births recorded in Washington State from 1987 to 1998. Mothers were classified (...) as having gestational hypertension, preeclampsia, or chronic hypertension based on hospital discharge and birth record information. Birth records were linked to subsequent hospitalizations within Washington State. Proportional hazards models were used to estimate the relationship between each form of pregnancy-related hypertension and subsequent risk for cardiovascular and thromboembolic events.We identified 31,239 eligible hypertensive pregnancies from 807,010 births. During follow-up, there were 118

2003 American Journal of Kidney Diseases

3771. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. (PubMed)

of venous thromboembolism was 1.72 per 1000 deliveries with 1.1 deaths per 100,000. The risk of venous thromboembolism was 38% higher for women ages 35 and older and 64% higher for black women. Other significant risk factors included thrombophilia, lupus, heart disease, sickle cell disease, obesity, fluid and electrolyte imbalance, postpartum infection, and transfusion. The risk factor with the highest odds ratio, 51.8 (38.7-69.2) was thrombophilia.The incidence of pregnancy-related venous (...) Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. The purpose of this study was to estimate the incidence, risk factors, and mortality from pregnancy-related venous thromboembolism.The Nationwide Inpatient Sample from the Healthcare Cost and Utilization Project of the Agency for Healthcare Research and Quality for the years 2000 to 2001 was queried for all pregnancy-related discharges with a diagnosis of venous thromboembolism.The rate

2006 American Journal of Obstetrics and Gynecology

3772. Prothrombin 20210A mutation: a mild risk factor for venous thromboembolism but not for arterial thrombotic disease and pregnancy-related complications in a family study. (PubMed)

Prothrombin 20210A mutation: a mild risk factor for venous thromboembolism but not for arterial thrombotic disease and pregnancy-related complications in a family study. The prothrombin 20210A mutation has been associated with an increased risk of venous thromboembolism (VTE). Its relationship with arterial disease and pregnancy-related complications is, however, still uncertain. The aim of this study was to estimate the incidences of first venous and arterial thrombotic events and pregnancy (...) a history of VTE in the proband influenced the risk of VTE in the relatives. Women with the mutation did not experience significantly more pregnancy-related complications than their relatives with a normal genotype.The prothrombin mutation is a mild risk factor for VTE within families of carriers but does not seem to play an important role in arterial thrombotic disease, with the exception of myocardial infarction, or in pregnancy-related complications.

Full Text available with Trip Pro

2004 Archives of Internal Medicine

3773. Oral contraceptives, pregnancy and the risk of cerebral thromboembolism: the influence of diabetes, hypertension, migraine and previous thrombotic disease. (PubMed)

Oral contraceptives, pregnancy and the risk of cerebral thromboembolism: the influence of diabetes, hypertension, migraine and previous thrombotic disease. To assess the risk of developing cerebral thromboembolism among pregnant women and among fertile women with hypertension, migraine, diabetes, and previous thrombotic disease, and to investigate the interaction of these risk factors with the use of oral contraceptives.A retrospective case-control study.All gynaecological, medical (...) an OR of 2.8 (P < 0.01). Women with previous non-cerebral thrombotic disease had an OR for cerebral thrombo-embolism of 5.3 (P < 0.001). Women with other predisposing medical diseases had an OR of 8.3 (P < 0.001). These ORs were identical among users and non-users of combined oral contraceptives.In this study pregnancy implied a non-significant elevated odds ratio of 1.3 for cerebral thromboembolism whereas diabetes, hypertension, migraine and past thromboembolic events increased the risk of cerebral

1995 British journal of obstetrics and gynaecology

3774. [Risk of osteoporosis in long-term heparin therapy of thromboembolic diseases in pregnancy: attempted prevention with ossein-hydroxyapatite]. (PubMed)

[Risk of osteoporosis in long-term heparin therapy of thromboembolic diseases in pregnancy: attempted prevention with ossein-hydroxyapatite]. Generalized idiopathic osteoporosis and transient osteoporosis of the hip are both rare complications of pregnancy. More frequently, long-term heparin administration to treat deep thrombosis in the legs or pelvis may lead to substantial decreases in bone mass and consequently increased risk of osteoporosis. Therapeutic studies with the aim to counteract (...) the osteoporosis inducing effect of heparins, have not been published to date. In the special situation of pregnancy, most medications used for osteoporosis are contraindicated. In our open randomised study, 9 women on heparin-treatment received daily 6.46 g of the bone preparation OHC (ossein-hydroxyapatite-compound) over a period of 6 months and were compared to 11 women without bone protective treatment. In the OHC-group, good compliance was observed with no side effects and reduced back pain. Bone mass did

1992 Geburtshilfe und Frauenheilkunde Controlled trial quality: uncertain

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>